Home
Live Updates
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting : vimarsana.com
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Australia ,
Japan ,
United States ,
New Zealand ,
Massachusetts ,
Boston ,
South Korea ,
Republic Of Korea ,
Matthew Deyoung ,
Douglase Onsi ,
Samuel Klempner ,
Samuelj Klempner ,
Cynthia Sirard ,
Michael Haas ,
Hospital Cancer Center ,
Beigene Ltd ,
Harvard Medical School ,
Nasdaq ,
Professor At Harvard Medical School ,
Prnewswire Leap Therapeutics Inc ,
Securities Exchange ,
Leap Therapeutics Inc ,
Society Of Immunotherapy ,
Annual Meeting ,
Associate Professor ,
Massachusetts General Hospital Cancer Center ,
Chief Medical Officer ,
Poster Details ,
Investigational Therapy ,
Gastroesophageal Adenocarcinoma ,
Harvard Medical ,
Immune Modulatory Activity ,
Robust Efficacy ,
Colorectal Cancer ,
Poster Session ,
Leap Therapeutics ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Leap Therapeutic ,
Annual Report ,
Quarterly Reports ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.